key: cord-0046042-uuzv5z0k
authors: Ilomäki, Jenni; Bell, J. Simon; Chan, Adrienne Y. L.; Tolppanen, Anna-Maija; Luo, Hao; Wei, Li; Lai, Edward Chia-Cheng; Shin, Ju-Young; De Paoli, Giorgia; Pajouheshnia, Romin; Ho, Frederick K.; Reynolds, Lorenna; Lau, Kui Kai; Crystal, Stephen; Lau, Wallis C. Y.; Man, Kenneth K. C.; Brauer, Ruth; Chan, Esther W.; Shen, Chin-Yao; Kim, Ju Hwan; Lum, Terry Y. S.; Hartikainen, Sirpa; Koponen, Marjaana; Rooke, Evelien; Bazelier, Marloes; Klungel, Olaf; Setoguchi, Soko; Pell, Jill P.; Cook, Sharon; Wong, Ian C. K.
title: Application of Healthcare ‘Big Data’ in CNS Drug Research: The Example of the Neurological and mental health Global Epidemiology Network (NeuroGEN)
date: 2020-06-22
journal: CNS Drugs
DOI: 10.1007/s40263-020-00742-4
sha: 4a09ca1d4fd34e19d6c66f7a6c8d736e4ca36677
doc_id: 46042
cord_uid: uuzv5z0k

Neurological and psychiatric (mental health) disorders have a large impact on health burden globally. Cognitive disorders (including dementia) and stroke are leading causes of disability. Mental health disorders, including depression, contribute up to one-third of total years lived with disability. The Neurological and mental health Global Epidemiology Network (NeuroGEN) is an international multi-database network that harnesses administrative and electronic medical records from Australia, Asia, Europe and North America. Using these databases NeuroGEN will investigate medication use and health outcomes in neurological and mental health disorders. A key objective of NeuroGEN is to facilitate high-quality observational studies to address evidence-practice gaps where randomized controlled trials do not provide sufficient information on medication benefits and risks that is specific to vulnerable population groups. International multi-database research facilitates comparisons across geographical areas and jurisdictions, increases statistical power to investigate small subpopulations or rare outcomes, permits early post-approval assessment of safety and effectiveness, and increases generalisability of results. Through bringing together international researchers in pharmacoepidemiology, NeuroGEN has the potential to be paradigm-changing for observational research to inform evidence-based prescribing. The first focus of NeuroGEN will be to address evidence-gaps in the treatment of chronic comorbidities in people with dementia.

Neurological disorders such as cognitive disorders (including dementia), stroke and Parkinson's disease are leading causes of dependence and disability worldwide [1, 2] . Dementia has a global annual cost of US$818 billion [3] . The prevalence of age-related neurodegenerative disorders, including dementia and Parkinson's disease, is expected to double over the next 20 years [1] . It was estimated that 43.8 million people were living with dementia in 2016 [4] , with 7.7 million new people being diagnosed every year [5] . Over 6 million people worldwide have Parkinson's disease, and the prevalence has doubled over a generation [6] . The total global burden of stroke is increasing, and close to 6 million people die because of stroke each year [7] . Psychiatric (mental health) disorders affect approximately 4.4% of the world's population at any one point in time, with an estimated 300 million people directly affected by depression in 2015 [8] . It is estimated that mental health disorders may be contributing to one-third of total years lived with disability, depression being the most common disorder [9] .

Optimizing care and support through appropriate pharmacological and non-pharmacological management can reduce burden in people with neurological and/or mental health disorders, their families, healthcare systems and society.

Neurological and mental health disorders have a disproportionately large impact on global disease burden, but people with these disorders are often underrepresented in randomized controlled trials and real-world evidence is lacking.

International multi-database research using administrative data and electronic medical records provides an opportunity to conduct large and generalizable observational studies to generate new evidence to inform prescribing.

The Neurological and mental health Global Epidemiology Network (NeuroGEN) addresses evidence-gaps in the treatment of neurological and mental health disorders by bringing together researchers and data from Australia, Asia, Europe and North America.

Reducing the social and economic burden of neurological and mental health disorders, including dementia, is a global health priority [3] . The World Health Organization (WHO) Ministerial Conference on Global Action Against Dementia highlighted the need for research to determine and ensure the optimal use of pharmacological treatments for symptoms of dementia [3] . There are currently clear evidence gaps affecting the quality of medication use in certain vulnerable populations, such as those with dementia. For example, participants included in randomized controlled trials (RCTs) do not necessarily represent the characteristics of people prescribed medications in routine clinical practice. Older people with neurological and mental health disorders are often excluded from RCTs [10] , resulting in a lack of evidence for medication safety and effectiveness. This is despite people with neurological and mental health disorders often experiencing high rates of multimorbidity and treatment with multiple medications [11, 12] . For example, few people with dementia were eligible to participate in the pivotal direct oral anticoagulant (DOAC) RCTs [13] , despite a high prevalence of cardiovascular and cerebrovascular disease in this population [11] . In RCTs of acetylcholinesterase inhibitors, participants have been notably younger than the reallife population with Alzheimer's disease [14] . Specific evidence regarding the benefits and risks of medications in people with dementia is lacking [10] , yet results of a recent nationwide study demonstrated that people with dementia were more likely to be exposed to polypharmacy (dispensed five or more medications) than people without dementia [15] . Insufficient evidence may lead to reliance on evidence extrapolated from other populations or settings, or prescribing decisions based on assumed benefits and risks. This could compound prescribing uncertainty or lead to inappropriate prescription of guideline-recommended medications for comorbid conditions. The UK primary care data suggest comorbid depression is diagnosed in 17%, 21%, 18% and 32% of people with coronary heart disease, stroke, diabetes and dementia, respectively [16] . Despite being highly prevalent, people with diagnosed depression are often excluded from RCTs related to the management of these conditions.

The rapid increase in the availability of administrative and electronic medical record (EMR) data has resulted in new potential for 'big data' research in medication safety and effectiveness [10] . These data are collected from hospitals, primary care medical practices and pharmacies. Clinical registries have also been established in primary and secondary care, often with linkage to administrative data. High-quality, multi-database, observational studies of such 'big data' enable comparisons across geographical areas and jurisdictions, an increase in statistical power to investigate small subpopulations, rare outcomes, early post-approval assessment of safety and effectiveness, and an increased generalisability of findings. 

NeuroGEN facilitates access to a global network of administrative and medical record data for the purpose of conducting multi-database observational research with a focus on neurological and mental health disorders. Collectively, data are available for an estimated 100 million people with and without neurological and mental health disorders. There are considerable differences in national regulations and the application of ethical frameworks in different countries, and therefore each NeuroGEN partner works with the relevant data custodians and ethics committees to comply with the local legal and ethical requirements. Data included in each of the databases are described in Table 1 .

Monash University's Centre for Medicine Use and Safety (CMUS) comprises investigators in pharmacoepidemiology and clinical pharmacy. One of the research priorities of the CMUS involves analyses of administrative claims data to optimize medication use for dementia and cardiovascular diseases [18, 19] . The primary data source is a 10% random sample of national dispensing data from Australia's Pharmaceutical Benefits Scheme (PBS). Data are available for 10% (≈ 2.5 million) of Australia's population. This dataset is provided in a standard de-identified form by Services Australia, by application. Other data include Victorian-wide hospital data linked to the PBS, general medical practitioner data obtained through the Medicare Benefits Schedule (MBS), and emergency department and mortality data. Victoria is the second most populous state in Australia, with a population of 6.6 million. Analyses of linked Victorian data have been approved by all data custodians, with a waiver of informed consent due to the retrospective use of the data, data provided to researchers are de-identified, and consent would not be feasible to obtain.

The University of Hong Kong (HKU) team has conducted multi-database pharmacoepidemiological studies using EMRs [20] [21] [22] . The primary source of data is the Clinical 

The UCL School of Pharmacy team's research focuses on neurodegenerative and cardiovascular diseases, diabetes, child health and pregnancy [23] [24] [25] . The main source of data is The Health Improvement Network (THIN). THIN is a nationwide database that contains electronic primary care records from UK general practices for 15 million individuals [26] . THIN covers a 6% representative sample of the UK population. Multiple diagnoses and lifestyle variables recorded in THIN database, including cardiovascular diseases, diabetes, obesity and smoking, have been used and validated for pharmacoepidemiological research [27] . THIN is subject to the UK Data Protection Act 2018 and EU General Data Protection Regulation (GDPR). Data obtained have been anonymised and consent was previously collected by the general practices where patients can opt-out.

The University of Glasgow has expertise on vascular neurological and cardiometabolic diseases [28] [29] [30] . The primary source of data is the UK Biobank, which recruited 502,536 participants, aged 39-72 years, from the general population between 2007 and 2010. Participants attended one of 22 assessment centres across England, Scotland, and, where they completed a self-administered questionnaire and face-to-face interview, and trained staff took a series of measurements, including height, weight and blood pressure. Mortality, hospitalization, and primary care consultations are available through data linkage. The UK Biobank has acquired explicit informed consent from all participants.

The MEMO (Medicines Monitoring Unit) Research group at the University of Dundee and Ninewells Hospital conducts observational studies [31, 32] and large decentralized clinical trials. MEMO currently have approximately 40,000 patients randomized into clinical trials. For pharmacoepidemiological studies, MEMO researchers use data from the Information Services Division (ISD) of National Services Scotland, which is part of the public National Health Service (NHS). The ISD provides health information, health intelligence, statistical services and advice that support the NHS with the goal to improve Scotland's health. The Service holds health-related data, which in some cases cover an individual from before birth (with the mother's antenatal records) to their death. The ISD complies with the NHS Scotland Information Security Policy set out by the Scottish Government (https ://www.infor matio ngove rnanc e.scot. nhs.uk/isfra mewor k/). Senior staff in the ISD have the role of 'Caldicott Guardian' (https ://www.gov.uk/gover nment / group s/uk-caldi cott-guard ian-counc il) for the Organization to ensure that not only the appropriate steps to protect the confidentiality of personal health information is observed but also that sensitive information is handled properly. In order to access personal health information, investigators are required to obtain a special authorization, and, once obtained, strict rules are in place to how information should be managed.

The National Cheng Kung University (NCKU) focuses on pharmacoepidemiology and big data research using claims data based on the National Health Insurance program in Taiwan [33, 34] . The National Health Insurance Database (NHID) was launched in 1995. The program covers over 99% of Taiwan's population (25 million people) and enrolled more than 90% of hospitals and clinics. The Ministry of Health and Welfare (MOHW) established a Health and Welfare Data Centre (HWDC), a data repository site that centralizes the NHID. The NHID includes medications, medical visits and procedures recorded in ambulatory, in-patient and emergency services. In addition, a multi-institutional EMR database, the Chang Gung Research Database (CGRD) [35] containing clinical data such as pathological and laboratory results, is available to serve as external validation data for the NHID. The CGRD includes 1.3 million outpatients and 0.2 million inpatients in Taiwan [36, 37] . Due to the retrospective nature of the analyses, informed consent is not required for either the NHID or the CGRD.

The Korean team focuses on analyses of the National Health Insurance System (NHIS) claims database [38, 39] and multi-database studies. 

The Kuopio Research Centre of Geriatric Care focuses on pharmacoepidemiology in people with Alzheimer's disease and Parkinson's disease. This includes aetiological research, drug utilization studies and outcome studies [40, 41] . Primary sources of data are the nationwide MEDication use and ALZheimer's disease (MEDALZ) study [42] on people with Alzheimer's disease, and the Finnish Medication and Parkinson's disease (FINPARK) study on people with Parkinson's disease [43] . Both studies include a matched cohort to facilitate comparisons to persons without these conditions and are derived from Finnish nationwide databases including medication dispensing data, hospital discharge data and mortality data. The MEDALZ cohort includes incident cases of Alzheimer's disease diagnosed from 2005 to 2011, and the FINPARK study includes incident cases of Parkinson's disease diagnosed from 1996 to 2015 with ongoing follow-up. Both MEDALZ and FINPARK data are used in pseudonymised form. The research proposals are approved by data custodians. According to Finnish legislation, other approvals or informed consent are not needed as the study is based on pseudonymized register data, and participants are not contacted.

The Pharmacoepidemiology and Clinical Pharmacy group at Utrecht University (UU) has a clinical, policy and methodological focus. The UU group has methodological expertise in preventing and/or controlling for confounding, analysis of effect modification and conducting multi-database analysis. The primary data sources used for large pharmacoepidemiological studies include the Dutch PHARMO database (http://www.pharm o.nl) and the UK Clinical Practice Research Datalink (CPRD) [44] . The CPRD is subject to the UK Data Protection Act 2018 and the EU GDPR. Data obtained have been anonymised and consent was previously collected by the general practices where patients can opt-out. In PHARMO, patient information is de-identified and the requirement for individual consent is waived unless an intervention is planned. All use of the data requires approval by the independent Compliance Committee STI-ZON/PHARMO Institute, in compliance with the Netherlands Personal Data Protection Act and Medical Treatment Contract Act. Data access is funded by the Utrecht Institute for Pharmaceutical Sciences. The UU group coordinate the European Research Network of Pharmacovigilance and Pharmacoepidemiology (EU PE&PV) and have developed novel methodologies for the conduct of multi-country, multidatabase studies on variability of medication use and health outcomes [45] [46] [47] .

The Center for Health Services Research and Center of the Pharmacoepidemiology and Treatment Sciences at Rutgers' Institute for Health are interdisciplinary groups with research focusing on the use and outcomes of medications across large, diverse usual-care populations in the US and other countries [48, 49] . Researchers at Rutgers have worked on studies particularly on the use and outcomes of central nervous system (CNS) drugs, including opioid use disorders; use and outcomes of antipsychotics; treatment of adults with severe mental illness; use and safety of selective serotonin reuptake inhibitors in pregnant women; and psychotropic treatment for children. The main data sources include health insurance data from the Center for Medicare and Medicaid Services, which is updated annually: a 20% sample of Medicare patients representative of the US older people and people with end-stage renal diseases, and 45 State Medicaid Analytic Extracts (MAX) representative of a low-income population, including pregnant women and children. According to the US Health Insurance Portability and Accountability Act (HIPAA) of 1996 privacy rules, informed consent was not required as the data were originally collected for insurance purposes, and secondary use of the data for researchers is conducted without person identifiers.

Acetylcholinesterase inhibitors (AChEIs) are the most widely prescribed medications for dementia, although efficacy [50, 51] and cost effectiveness [51, 52] are modest. Non-adherence and non-persistence reduce potential benefits, with a systematic review of five RCTs reporting that discontinuation is associated with a significant decline in cognition and worsening of neuropsychiatric symptoms [53] . This highlights the importance of persistence in maximising benefit. This study will investigate adherence and persistence to AChEIs across the NeuroGEN partners. Australia, South Korea and Taiwan have analysed their respective data using a common study protocol. The study will utilize the proportion of days covered to estimate adherence from medication dispensing and prescribing databases. Persistence will be estimated using a prespecified gap of no dispensing or prescribing. This study will permit a comparison adherence and persistence using standardized definitions and methodology. This program of work is funded through the National Health and Medical Research Council (NHMRC) Boosting Dementia Leadership Fellowship Scheme.

Based on the 'cognitive footprint' of medical history, this population-based, case-control study will aim to develop and validate an algorithm for predicting dementia using machine learning [54] . The algorithm will be trained using territory-wide EMRs from the CDARS in Hong Kong, and tested both locally and externally in other databases (e.g. the UK THIN and the Finnish MEDALZ). The CDARS currently hosts records from more than 70,000 people with dementia diagnoses between 2001 and 2018. Potential protective/risk factors, which will be selected based on the cognitive footprint theory, will be modelled holistically. It is anticipated that the modelling will include analyses of diagnostic data, laboratory test results and the prescription of antidepressants, antipsychotics, statins and polypharmacy. Other than a set of Hong Kong-specific factors, a set of common factors that are shared by other databases will be identified to maximize interoperability. The subsequent common algorithm, to be derived from real-world data in Hong Kong, may then be suitable for embedding into other health information systems. Patients with a high risk or likelihood of dementia can be efficiently identified to permit targeting of risk-reduction programs. A secondary objective of this project is to estimate survival from the point of a recorded diagnosis of dementia in Hong Kong, Canada, Finland, Germany, Korea, Taiwan, UK and US. This project will aggregate large population-scale data from different geographical regions. The project is ongoing and is expected to be completed by June 2022. This project is funded by the Research Grant Council of Hong Kong under the Early Career Scheme.

In a meta-analysis of inception cohorts, Parkinson's disease was associated with 1.5 times higher mortality [55] .

The same meta-analysis demonstrated major heterogeneity in mortality ratios stratified by sex, and identified a need for further high-quality studies of mortality in Parkinson's disease. Specifically, there is a lack of large-scale, population-based inception cohorts with long-term follow-up. This study will investigate the survival of people with Parkinson's disease following diagnosis, as well as possible geographical differences in mortality ratios and factors that predict higher mortality. The project is in its initiation phase. This project will be coordinated from Finland, and data from Finland, Hong Kong, Korea, Australia and the UK will be utilized. Additional countries will be included once confirmed with the corresponding investigators. Funding applications for this project have been submitted. Once secured, the development of the common study protocol will commence.

One of the objectives of NeuroGEN is capacity building and training the next generation of pharmacoepidemiologists. This is being achieved by providing opportunities to early career researchers, including PhD candidates and post-doctoral researchers. 

Multinational collaboration with data from multiple regions globally is a growing opportunity to conduct large, generalizable, observational studies that address research questions with international relevance. Use of a common protocol approach (CPA) and common data models (CDM) can facilitate large multi-database studies that address topics of international public health importance. NeuroGEN is currently using both the CPA and CDM. Although the CPA is more straightforward to implement, it requires close communication between investigators to ensure that all analyses are conducted consistently. A CDM is a sophisticated data platform supporting secondary use of data across multiple databases. The major advantage of CDM is that analyses are controlled by the use of a standardized data structure, terminology, variable definitions and an analytical program. Such a distributed network approach in which data partners maintain physical and operational control over the data in their existing environments also addresses data privacy issues across jurisdictions because data are not shared. However, establishing the CDM requires a considerable investment of time and resources to convert native databases into the CDM. Other examples of consortia include the Asian Pharmacoepidemiology Network (AsPEN). AsPEN uses modified distributed networks with a common data structure across databases to allow single analytic programs to be used in each site [61] . Some NeuroGEN investigators are also participating in AsPEN. Another example is the Canadian Network for Observational Drug Effect Studies (CNODES), where databases across different provinces are analysed using the same approach [62] .

NeuroGEN investigators have created a CDM based on the Observational Medical Outcomes Partnership (OMOP) CDM [63] , containing all relevant information to conduct analyses for ongoing projects. A stand-alone analysis programme for each study will be developed based on the Neu-roGEN CDM. Because the data structure and terminologies are identical among the converted databases, the analyses can be conducted in each home institution. Each site will generate a standardized results file that will then be collected by the coordinating site. Figure 2 presents the structure of the NeuroGEN CDM. Previous applications of similar conversions include, for example, paediatric use of prescription medications [64] .

Dementia Australia and the Yulgilbar Foundation have funded the development of the CDM for four databases focusing on dementia research. The databases include the Australian linked health data, the US Medicare data, the UK THIN data and the Hong Kong CDARS data. The respective investigators are currently working together synchronising the databases into the CDM format to investigate the use of guideline-recommended medications for chronic comorbidities in people with and without dementia.

NeuroGEN is planning an international symposium on multi-database pharmacoepidemiology and is currently in discussion with partner research groups in other geographical regions, including Oceania and South America. Currently the COVID-19 is posing significant challenges globally, a large volume of research has been produced on the acute effects and acute treatments. However, the medium and long-term direct and indirect effects of COVID-19, impact on the pandemic on management of non-COVID related conditions, and the mental health and wellbeing of society as a whole remain unknown. Partners of NeuroGEN are currently working together to develop research proposals for various funding bodies. These proposals will harness the power of big data in monitoring the medium and long-term outcomes of COVID-19 as well as other novel infectious diseases and the effectiveness and safety of future vaccines and interventions. The collaboration will continue to seek to address topics of global importance to better manage neurological and mental health disorders. 

NeuroGEN is a recent initiative addressing medication use and outcomes in people with neurological and mental health disorders. Compared with the other multi-database initiatives, NeuroGEN is the only global multi-database network that specifically addresses the management of neurological and mental health conditions, and with a broader focus on psychopharmacology. This will address significant evidence gaps in this under researched field. NeuroGEN covers countries and regions across four continents, Australia, Asia, Europe and North America, making the initiative truly global.

Burden of neurodegenerative diseases in the Eastern Mediterranean Region, 1990-2016: findings from the Global Burden of Disease Study

Global burden of stroke and risk factors in 188 countries, during 1990-2013: a systematic analysis for the Global Burden of Disease Study

Research priorities to reduce the global burden of dementia by 2025

Global, regional, and national burden of Alzheimer's disease and other dementias, 1990-2016: a systematic analysis for the Global Burden of Disease Study

Dementia: a public health priority. Geneva: World Health Organization

GBD Parkinson's Disease Collaborators. Global, regional, and national burden of Parkinson's disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study

a systematic analysis for the Global Burden of Disease Study

World Health Organization. Depression and other common mental disorders: Global health estimates. Geneva: World Health Organization

Estimating the true global burden of mental illness

Using clinical registries, administrative data and electronic medical records to improve medication safety and effectiveness in dementia

Comorbidity and polypharmacy in people with dementia: insights from a large, population-based cross-sectional analysis of primary care data

Comorbid conditions associated with Parkinson's disease: a longitudinal and comparative study with Alzheimer disease and control subjects

Prevalence, safety, and effectiveness of oral anticoagulant use in people with and without dementia or cognitive impairment: a systematic review and meta-analysis

Systematic review: representativeness of participants in RCTs of acetylcholinesterase inhibitors

Polypharmacy and potentially inappropriate medication in people with dementia: a nationwide study

Adapting clinical guidelines to take account of multimorbidity

Neurological and mental health Global Epidmeiology Network (NeuroGEN)

Trends and predictors of oral anticoagulant use in people with Alzheimer's disease and the general population in Australia

Adherence, persistence, and switching among people prescribed sodium glucose co-transporter 2 inhibitors: a nationwide retrospective cohort study

Trends in attention-deficit hyperactivity disorder medication use: a retrospective observational study using population-based databases

Prenatal antidepressant use and risk of attention-deficit/ hyperactivity disorder in offspring: population based cohort study

Association of risk of suicide attempts with methylphenidate treatment

Trazodone use and risk of dementia: a population-based cohort study

Incidence of type 2 diabetes mellitus in men receiving steroid 5alpha-reductase inhibitors: population based cohort study

Association between cardiovascular events and sodium-containing effervescent, dispersible, and soluble drugs: nested case-control study

Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates

Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research

Associations of fat and carbohydrate intake with cardiovascular disease and mortality: prospective cohort study of UK Biobank participants

Glycated hemoglobin, prediabetes, and the links to cardiovascular disease: data from UK Biobank

Sex differences in the association of risk factors for heart failure incidence and mortality

cardiovascular safety of prucalopride in patients with chronic constipation: a multinational population-based cohort study

Spironolactone use and risk of incident cancers: a retrospective, matched cohort study

Use of hydrochlorothiazide and risk of skin cancer: a nationwide Taiwanese case-control study

Taiwan's National Health Insurance Research Database: past and future

The Chang Gung Research Database: a multi-institutional electronic medical records database for real-world epidemiological studies in Taiwan

Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi-institutional cohort study

Sodium glucose co-transporter 2 inhibitors and cardiovascular event protections: how applicable are clinical trials and observational studies to real-world patients?

Association between acetylcholinesterase inhibitors and osteoporotic fractures in older persons with Alzheimer's disease

Anticholinergic use among the elderly with Alzheimer disease in South Korea: a populationbased study

Long-term thiazide use and risk of low-energy fractures among persons with Alzheimer's disease-nested casecontrol study

The risk of head injuries associated with antipsychotic use among persons with Alzheimer's disease

Cohort profile: the Finnish Medication and Alzheimer's disease (MEDALZ) study

Incidence of muscle relaxant use in relation to diagnosis of Parkinson's disease

Data resource profile: clinical practice research datalink (CPRD)

How pharmacoepidemiology networks can manage distributed analyses to improve replicability and transparency and minimize bias

Incidence of direct oral anticoagulant use in patients with nonvalvular atrial fibrillation and characteristics of users in 6 European countries

Multiple sclerosis and fracture risk: traditional meta-analysis versus mega-analysis of individual patient data

Acute care, prescription opioid use, and overdose following discontinuation of long-term buprenorphine treatment for opioid use disorder

Comparative Effectiveness of adjunctive psychotropic medications in patients with schizophrenia

Rivastigmine for Alzheimer's disease

Donepezil for dementia due to Alzheimer's disease

The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model

Cholinesterase inhibitor discontinuation in patients with Alzheimer's disease: a meta-analysis of randomized controlled trials

Can we model a cognitive footprint of interventions and policies to help to meet the global challenge of dementia?

Mortality in Parkinson's disease: a systematic review and meta-analysis

Safety and effectiveness of direct oral anticoagulants vs warfarin in people with atrial fibrillation and dementia

Oral anticoagulant and reduced risk of dementia in patients with atrial fibrillation: a population-based cohort study

Oral anticoagulants and risk of dementia: a systematic review and meta-analysis of observational studies and randomized controlled trials

Prevalence and incidence of dementia in people with diabetes mellitus

Metformin and risk of Alzheimer's disease among community-dwelling people with diabetes: a national case-control study

Applying a common data model to Asian databases for multinational pharmacoepidemiologic studies: opportunities and challenges

The Canadian Network for Observational Drug Effect Studies (CNODES): reflections on the first eight years, and a look to the future

Creating a common data model for comparative effectiveness with the observational medical outcomes partnership

Application of a Common Data Model (CDM) to rank the paediatric user and prescription prevalence of 15 different drug classes in South Korea